One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration

Purpose To investigate 1-year visual and anatomic outcomes of intravitreal aflibercept for neovascular age-related macular degeneration (nAMD) given at a fixed 8-weekly interval. Methods Retrospective, single-practice data analysis from an electronic medical record system of 255 eyes (223 patients)...

Full description

Saved in:
Bibliographic Details
Published in:Eye (London) 2017-06, Vol.31 (6), p.878-883
Main Authors: Almuhtaseb, H, Kanavati, S, Rufai, S R, Lotery, A J
Format: Article
Language:English
Subjects:
692/699/3161/1626
692/700/3934
692/700/565/1436
Aged, 80 and over
Clinical Study
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Fluorescein Angiography
Follow-Up Studies
Fundus Oculi
Humans
Intravitreal Injections
Laboratory Medicine
Male
Medicine
Medicine & Public Health
Ophthalmology
Pharmaceutical Sciences/Technology
Receptors, Vascular Endothelial Growth Factor - administration & dosage
Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors
Recombinant Fusion Proteins - administration & dosage
Retina - pathology
Retrospective Studies
Surgery
Surgical Oncology
Tomography, Optical Coherence
Treatment Outcome
Visual Acuity
Wet Macular Degeneration - diagnosis
Wet Macular Degeneration - drug therapy
Wet Macular Degeneration - physiopathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose To investigate 1-year visual and anatomic outcomes of intravitreal aflibercept for neovascular age-related macular degeneration (nAMD) given at a fixed 8-weekly interval. Methods Retrospective, single-practice data analysis from an electronic medical record system of 255 eyes (223 patients) with treatment-naïve nAMD receiving 8-weekly aflibercept. Results Mean logarithm of the minimum angle of resolution best-corrected visual acuity (BCVA) improved from 0.66 at baseline to 0.50 at month 11 ( P
ISSN:0950-222X
1476-5454
DOI:10.1038/eye.2017.6